stockrow
Friday 6 November 2026
Export SERA’s income statement to Excel — free account
Sera Prognostics, Inc.
SERA Healthcare Medical Devices
Sera Prognostics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $81,000.00, up 5.19% from fiscal 2024.
- Revenue
- +162.5%
- EPS
- +0.88%
- Free cash flow
- −12.8%
Quarter to September 2026, against a year earlier
2.16
0.08
+3.85%
Follow SERA
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,105.74 | 1,312.40 | 1,789.92 | 1,735.84 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(14.55) | (14.56) | (11.63) | (22.97) | |
P/B ratio |
2.02 | 1.55 | 1.51 | 1.86 | |
Price to Tangible BV |
2.06 | 1.57 | 1.53 | 1.89 | |
EV/Sales |
646.50 | 648.93 | 958.36 | 1,251.90 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.18) | (1.64) | (2.03) | (3.96) | |
EV/FCF |
(2.11) | (1.59) | (1.91) | (3.70) | |
Quick Ratio |
1.80 | 1.91 | 2.02 | 1.62 | |
Current Ratio |
1.88 | 1.98 | 2.12 | 1.69 | |
Net Debt/EBITDA |
5.07 | 4.73 | 5.17 | 4.50 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 0.69 | 1.04 | 0.78 | |
Capex/Depreciation |
(0.70) | (0.27) | (0.04) | (1.35) | |
Interest Coverage |
(4,443.50) | (5,002.00) | (4,680.00) | (8,954.00) | |
Research and Development Expense of Revenue |
6,480.95% | 11,643.33% | 21,642.86% | 32,160.00% | |
Selling, General and Administrative Expense of Revenue |
14,633.33% | 21,636.67% | 45,014.29% | 57,060.00% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
3,050.00% | 2,743.33% | 5,964.29% | 10,190.00% | |
Graham Net Nets |
0.18 | 0.23 | 0.23 | 0.10 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(31.99%) | (36.81%) | (32.02%) | (23.05%) | |
Free Cash Flow Yield |
(27.67%) | (31.06%) | (28.05%) | (19.48%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.12) | (0.17) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.15) | (0.13) | (0.17) | (0.14) | |
Cash per Share |
0.87 | 0.92 | 0.94 | 0.82 | |
Shareholders Equity per Share |
1.03 | 1.18 | 1.35 | 1.58 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.03 | 1.18 | 1.35 | 1.58 | |
Free Cash Flow |
(7.43) | (6.36) | (8.78) | (6.45) | |
Working Capital |
21.69 | 23.78 | 26.31 | 16.58 | |
Capital Expenditures |
(0.13) | (0.05) | (0.01) | (0.33) | |
Net Current Asset Value |
18.68 | 20.78 | 23.80 | 14.25 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
3.19 | 1.73 | 0.57 | 33.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.02 | 0.01 | 0.02 | 0.02 | |
Average Payables |
1.10 | 1.13 | 0.99 | 1.42 | |
Average Assets |
94.05 | 99.28 | 105.86 | 87.25 | |
Average Common Equity |
67.31 | 73.80 | 81.20 | 61.61 |
Columns are period end dates · fundamentals updated 6 Nov 2026